Prevail Therapeutics
Private Company
Total funding raised: $287M
Overview
Prevail Therapeutics is a clinical-stage gene therapy company targeting neurodegenerative and rare diseases, most notably Parkinson's disease associated with GBA1 mutations and Gaucher disease. Its approach utilizes adeno-associated virus (AAV) vectors to deliver functional genes directly to the central nervous system, aiming to restore critical enzyme function. The company was acquired by Eli Lilly and Company in 2021, providing it with significant resources and strategic backing. Its lead program, PR001, is in clinical development for both GBA1-Parkinson's disease and neuronopathic Gaucher disease.
Technology Platform
AAV (Adeno-Associated Virus) vector-based gene therapy platform designed for direct delivery to the central nervous system (e.g., intra-cisterna magna infusion) to target the root genetic causes of disease.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Prevail faces competition from other gene therapy companies (e.g., Voyager Therapeutics, Axovant) and biopharma firms developing small molecules, ASOs, and other biologics for GBA1-PD and Parkinson's disease (e.g., Biogen, Sanofi, UCB). In neuronopathic Gaucher disease, while enzyme replacement therapy exists for systemic symptoms, Prevail is a front-runner in developing a direct CNS treatment, competing with approaches from companies like AVROBIO and Freeline.